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Introduction: We compared the pathologic outcomes of prostate cancer patients who did not
qualify for active surveillance according to the tumor visibility on multiparametric magnetic
resonance imaging.
Material and methods: We retrospectively analyzed 464 prostate cancer patients who
underwent multiparametric magnetic resonance imaging before radical prostatectomy
between 2006 and 2012. All the patients had clinically localized prostate cancer with Gleason
score 6 and prostate-specific antigen 10 ng/ml. Of these patients, 238 were eligible for
active surveillance (group A) and 226 were not. We divided these 226 patients into two
groups according to the result of multiparametric magnetic resonance imaging: 59 (26.1%)
patients without visible tumor (group B) and 167 (73.9%) patients with visible tumor (group
C). We evaluated the pathologic outcomes of organ-confined Gleason 6 disease and un-
favorable disease in each group.
Results: The proportions of organ-confined Gleason 6 disease and unfavorable disease
were 63.9 and 11.3% in group A, 59.3 and 10.2% in group B, and 38.9 and 22.8% in Group
C. Comparing group A and B, these proportions were not statistically different (P ¼ 0.549 and
P ¼ 1.000, respectively). However, comparing group A and C, those were significantly differ-
ent (P, 0.001 and P ¼ 0.002, respectively). In multivariate logistic regression analysis, no
visible tumor on multiparametric magnetic resonance imaging was an independent predictor
of organ-confined Gleason score 6 disease (odds ratio 0.426, P ¼ 0.007) but there was no
statistically independent predictor for unfavorable disease.
Conclusions: The tumor visibility on multiparametric magnetic resonance imaging could be
a predictor of favorable disease for the prostate cancer patients who did not meet active sur-
veillance criteria. Multiparametric magnetic resonance imaging could help to determine treat-
ment modality for the low-risk prostate cancer patients who consider active surveillance even
if they did not meet active surveillance criteria.
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INTRODUCTION
The increase in diagnosis of low-risk prostate cancer due to
widespread prostate-speciﬁc antigen (PSA) screening trig-
gered the investigation for an alternative treatment with
fewer morbidities and complications than radical prostatec-
tomy (RP). To this end, active surveillance (AS) was recent-
ly developed (1–5). Ideal candidates for AS are low-risk
prostate cancer patients with insigniﬁcant prostate cancer.
And also, low-risk prostate cancer patients with organ-
conﬁned Gleason score 6 disease could be AS candidates
considering the indolent quality of prostate cancer (6,7). To
identify AS candidates, several investigators developed their
own methods, which have been independently validated and
compared with regard to effectiveness (1–5).
Current patient inclusion criteria for AS programs are typic-
ally based on the proﬁles of prostate biopsy result, prostate-
speciﬁc antigen (PSA), PSA density (PSAD) and clinical
staging. According to the pathologic results of RP specimens
of AS candidates, the diagnostic accuracy was similar between
AS protocols (8,9). However, urologist frequently experienced
the low-risk prostate cancer patients who had insigniﬁcant
prostate cancer or organ-conﬁned Gleason score 6 disease
after RP even if they did not meet the AS protocols.
To overcome this misclassiﬁcation according to typical
AS inclusion criteria, multiparametric-MRI (MP-MRI) was
received attention recently. Several investigators reported
that MP-MRI might help to predict tumor size, tumor
aggressiveness and also to select AS candidates (10–14).
Taken these recent results together, we supposed that simple
tumor visibility on MP-MRI could help to identify the mis-
classiﬁed AS candidates who has favorable prostate cancer
among prostate cancer patients who did not meet AS criteria.
The aim of present study is to identify whether MP-MRI
could help to predict organ-conﬁned Gleason score 6
disease among the non-AS criteria according to tumor
visibility.
PATIENTS AND METHODS
We reviewed the records of 464 prostate cancer patients who
underwent MP-MRI before RP between 2006 and 2012. All
the patients had clinically localized Gleason score 6 prostate
cancer with preoperative prostate-speciﬁc antigen (PSA)
10 ng/ml. And they had complete medical records includ-
ing prostate biopsy proﬁles. We stratiﬁed these patients
according to AS protocol as deﬁned by Prostate Cancer
Research International: Active Surveillance (PRIAS). The in-
clusion criteria of PRIAS includes: Gleason score 6 on
biopsy, clinical stage T1c-T2, PSA 10 ng/ml, PSAD
0.2 ng/ml/cm3 and no more than two positive cores. We
used the PRIAS protocol to select AS candidates because
our previous analyses show that this protocol is the most
helpful in our cohort (9). Among them, we identiﬁed 238
(51.3%) patients who met the AS criteria and deﬁned these
patients as group A. The remaining 226 (48.7%) patients
who did not meet AS criteria; 89 patients did not meet AS
criteria due to number of positive biopsy cores, 84 patients
due to PSAD and 53 patients due to both criteria. We
divided these 226 non-AS candidates into two groups
according to the presence of visible tumor on MP-MRI: 59
(26.1%) patients had no visible tumor (group B), and 167
(73.9%) patients had visible tumor (group C).
For clinical staging, all patients were imaged using a
3.0-T MRI system (Intera Achieva 3.0 T, Phillips Medical
System, Best, The Netherlands), equipped with a
phased-array coil (six-channel). All patients underwent
diffusion-weighted (DW) MRI in addition to the routine
prostate MRI protocol of our institution. Two b values (0–
1000) were used, and the restriction of diffusion was quanti-
ﬁed by apparent diffusion coefﬁcient mapping. T2-weighted
(T2W) turbo spin-echo images were acquired in three or-
thogonal planes (axial, sagittal and coronal), and dynamic
contrast-enhanced MRI (DCE-MRI) was also obtained. The
average period between prostate biopsy and MRI was
27.4+ 19.1 days. All images were reviewed by two experi-
enced uroradiologists who were blinded to the pathologic
results. Patients who were suspected extraprostatic extension
(ECE) and/or seminal vesicle invasion on MP-MRI, were
excluded from study cohort even if they had normal digital
rectal examination ﬁnding.
We collected the following clinicopathologic outcomes:
age, prostate volume, preoperative PSA, PSAD, number of
total biopsy cores, number of positive biopsy cores, maximal
tumor diameter on MP-MRI, postoperative Gleason score,
pathologic stage, ECE, SVI, tumor volume and biochemical
recurrence (BCR).
To compare the clinicopathologic outcomes, the chi-
square test and independent t-test were used for statistical
comparison of categorical and continuous variables, respect-
ively. To assess the efﬁcacy of tumor visibility on MP-MRI
to reclassify AS candidate among non-AS group (groups B
and C), we compared the proportion of organ-conﬁned
Gleason score 6 disease and unfavorable disease with
those of AS candidate (group A) as the standard criteria.
Unfavorable disease features were deﬁned as prostate cancer
with postoperative Gleason score 8–10 and/or ECE and/or
SVI. Multivariate logistic regression analysis was performed
to identify predictors for organ-conﬁned Gleason score 6
disease and unfavorable disease features in the RP speci-
mens. The actual risk of BCR was calculated using the
Kaplan–Meier method. All statistical analyses were per-
formed using SPSS v.18.0 software (SPSS, Chicago, IL,
USA). A P value of 0.05 was considered statistically
signiﬁcant.
RESULTS
The baseline characteristics of patients are shown in Table 1.
Among 464 prostate cancer patients, the mean preoperative
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PSA was 5.79 ng/ml and the mean PSAD was 0.18 ng/ml/cm3.
In overall study cohort, no visible tumor on MP-MRI was
found in 135 (29.1%) patients and 329 (70.9%) patients had
visible tumor. Among AS candidates, 76 of 238 (31.9%) had
no visible tumor on MP-MRI. Comparing the clinical para-
meters between non-AS groups (group B and group C), pre-
operative PSA and PSAD were signiﬁcantly different. The
mean preoperative PSA was 5.74+ 1.9 ng/ml in group B
and 6.48+ 1.7 ng/ml in group C (P ¼ 0.009), and the mean
PSAD was 0.20+ 0.07 in group B and 0.23+ 0.09 in group
C (P ¼ 0.012). However, there were no statistically signiﬁ-
cant differences in age, prostate volume, number of positive
biopsy cores between two groups. To compare maximal
diameter of visible tumor on MP-MRI, we compared visible
tumors between group A and group C. Group A had a
smaller tumor diameter than group C (14.2+ 6.8 versus
16.6+ 7.9 mm, P ¼ 0.004).
Table 2 shows the pathologic outcomes according to
tumor visibility on MP-MRI in AS candidates (group A). In
group A, the proportion of organ-conﬁned Gleason score 6
disease and unfavorable disease features were 67.1 and
11.8% in AS candidates who had no visible tumor and 62.3
and 11.1% in AS candidates who had visible tumor. These
proportions were not signiﬁcantly different (P ¼ 0.476 and
P ¼ 0.868). However, tumor volume was signiﬁcantly
smaller in AS candidates without visible tumor than those
with visible tumor (0.61+ 0.81 versus 0.98+ 1.05, P ¼
0.007).
In the overall study cohort, the proportion of organ-
conﬁned Gleason score 6 disease and unfavorable disease
features were 54.3 and 15.3% (Table 3). Comparing between
group A and group B, there were no statistical differences in
the distribution of postoperative Gleason scores, pathologic
stages, tumor volume, organ-conﬁned Gleason 6 disease
and unfavorable disease features. However, comparing
between group A and group C, there were statistical differ-
ences in the distribution of postoperative Gleason scores,
pathologic stages, tumor volume. And the proportion of
organ-conﬁned Gleason 6 disease and unfavorable disease
were also signiﬁcantly different (63.9 versus 38.9%, P,
0.001 and 11.3 versus 22.8%, P ¼ 0.002). After a mean post-
operative follow-up of 30 months, a log-rank test of the
Kaplan–Meier survival curves demonstrated no signiﬁcant
difference in overall BCR rate across each groups (Fig. 1,
log rank P ¼ 0.500).
Table 1. Baseline patient characteristics of active surveillance (AS) candidates (group A), non-AS candidates without visible tumor on MP-MRI (group B),
non-AS candidates with visible tumor on MP-MRI (group C)
Group A Group B Group C P value
No. of patients 238 59 167
Age 63.6+6.9 61.9+7.5 63.5+7.2 0.158a
PSA 5.32+1.6 5.74+1.9 6.48+1.7 0.009a
Prostate volume 42.9+15.7 30.3+11.7 30.5+10.7 0.916a
PSA density 0.13+0.04 0.20+0.07 0.23+0.09 0.012a
MRI result No visible tumor Visible tumor – – –
76 162 – – –
Maximal tumor diameter (mm) – 14.2+6.8 – 16.6+7.9 0.004b
No. of biopsy cores 11.8+2.4 11.6+2.6 11.6+1.7 0.998a
No. of positive cores 1.35+0.5 3.00+1.9 3.43+2.2 0.152a
MRI, magnetic resonance imaging; PSA, prostate-speciﬁc antigen.
aGroup B versus group C.
bGroup A and group C.
Table 2. Comparison of pathologic outcomes according to tumor visibility
on MP-MRI among AS candidates (group A)
No visible
tumor
Visible
tumor
P
value
Postoperative Gleason score
6 55 110 0.713
7 20 48
8–10 1 4
Pathologic stage
pT2 68 145 0.994
pT3 8 17
Extracapsular extension 8 (10.5%) 16 (9.9%) 0.877
Seminal vesicle invasion 0 (0.0%) 1 (0.6%) 0.492
Tumor volume 0.61+0.81 0.98+1.05 0.007
Organ-conﬁned Gleason score 6
disease
51 (67.1%) 101 (62.3%) 0.476
Unfavorable prostate cancer 9 (11.8%) 18 (11.1%) 0.868
Biochemical recurrence 4 (5.3%) 14 (8.7%) 0.358
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Using multivariate logistic regression analysis to predict
pathologic appearance in the non-AS candidates (group B
and C) according to the tumor visibility on MP-MRI, we
found that no visible tumor on MP-MRI was an independent
predictor of organ-conﬁned Gleason score 6 disease (odds
ratio ¼ 0.426, P ¼ 0.007). However, no preoperative param-
eter was an independent predictor of unfavorable disease
features. Even though there was no statistically signiﬁcance,
PSAD had higher odds ratio than other preoperative para-
meters (Table 4).
DISCUSSION
The increasing incidence of low-risk prostate cancer is an
ongoing worldwide phenomenon, and the increased number
of diagnoses of clinically localized prostate cancer is re-
markable in comparison with the number in past decades
(15). Using deﬁnitive therapy such as RP, clinically localized
prostate cancer might be curatively treated, especially in
Table 3. Comparison of pathologic outcomes between overall AS candidates (group A), non-AS candidates without visible tumor on MP-MRI (group B),
non-AS candidates with visible tumor on MP-MRI (group C)
Group A Group B Group C P value* P value**
Postoperative Gleason score
6 165 36 82 0.426 ,0.001
7 68 22 80
8–10 5 1 5
Pathologic stage
pT2 213 54 130 0.643 0.001
pT3 25 5 37
Extracapsular extension 24 (10.1%) 5 (8.5%) 33 (19.8%) 0.709 0.006
Seminal vesicle invasion 1 (0.4%) 0 (0.0%) 4 (2.4%) 0.618 0.076
Tumor volume 0.81+0.78 0.93+0.85 1.66+1.33 0.959 ,0.001
Organ-conﬁned Gleason score 6 disease 152 (63.9%) 35 (59.3%) 65 (38.9%) 0.549 ,0.001
Unfavorable prostate cancer 27 (11.3%) 6 (10.2%) 38 (22.8%) 1.000 0.002
Biochemical recurrence 18 (7.5%) 5 (8.5%) 16 (9.7%) 0.788 0.473
*P value, group A versus group B.
**P value, group A versus group C.
Figure 1. Comparison of Kaplan–Meier biochemical recurrence-free sur-
vival curves among the three groups after radical prostatectomy. Active sur-
veillance (AS) candidates (group A), non-AS candidates without visible
tumor on MP-MRI (group B), non-AS candidates with visible tumor on
MP-MRI (group C).
Table 4. Multivariate logistic regression analysis to predict organ-conﬁned
Gleason score 6 disease and unfavorable disease features using
preoperative variables in the non-AS candidates
Organ-conﬁned
Gleason 6 disease
Unfavorable prostate
cancera
Odds ratio P value Odds ratio P value
Age 1.011 0.569 1.008 0.500
PSA 0.980 0.831 0.903 0.401
PSA density 1.329 0.880 58.385 0.070
MRI result
No visible tumor Ref. – Ref. –
Visible tumor 0.426 0.007 2.527 0.053
No. of positive cores 0.999 0.993 0.963 0.666
aExtracapsular extension and/or seminal vesicle invasion and/or Gleason
score 8–10.
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low-risk prostate cancer patients. However, for the low-risk
prostate cancer patient with insigniﬁcant prostate cancer, RP
is obviously an overtreatment considering the morbidities,
postoperative complications and the oncologic features of in-
signiﬁcant prostate cancer. Considering the long-term
follow-up result of AS, it could be one of the treatment
options for low-risk prostate cancer patients (6).
To reduce overtreatment of these patients, several investi-
gators have promoted their AS programs (1–5). Several AS
protocols were developed with clinical results based on their
study cohort and the predictive accuracy for organ-conﬁned
Gleason 6 disease and insigniﬁcant prostate cancer were
not bad and quite similar according to their inclusion criteria
(8,9). Nevertheless, the dilemma of AS is still how to select
the ideal candidates more accurately. To select the ideal AS
candidates is important in the aspect of oncological safety of
AS. However, it is also important to reduce the number of
misclassiﬁed AS candidates who had favorable disease
among the patients who did not meet the AS inclusion cri-
teria in the aspect of the beneﬁts of AS. In clinical practice,
we frequently experienced that the patients who had organ-
conﬁned Gleason 6 disease including insigniﬁcant prostate
cancer among the low-risk prostate cancer patients who
excluded from AS inclusion criteria. So, many urologists
believe that typical AS inclusion criteria are not insufﬁcient
to identify AS candidates and have tried to investigate ways
to improve the accuracy of patient selection for AS. For
these reasons, the effectiveness of MP-MRI has been a focus
of current studies.
Prostate MRI has signiﬁcant value for the identiﬁcation of
ECE and SVI (16–18). However, these beneﬁts were primar-
ily seen in intermediate- and high-risk prostate cancer
patients, and the role of MRI for low-risk prostate cancer
patients was unclear (19). Several investigators raised variety
of opinions about the efﬁcacy of MRI for low-risk prostate
cancer patients. Vargas et al. (20) reported that tumor visual-
ization on T2W-MRI could help to assess eligibility for AS.
However, Guzzo et al. (21) concluded that tumor visibility
on T2W-MRI is not predictive of pathologic feature at RP
specimens, and that T2W-MRI could not provide additional
information for the selection of AS candidate. And also,
Ploussard et al. (22) concluded that T2W-MRI did not
improve the prediction of unfavorable prostate cancer under
the extended 21-core biopsy scheme. However, these articles
were based on the ﬁndings of T2W-MRI. The authors dis-
cussed additionally that other MRI techniques such as
MP-MRI including DW-MRI, MR spectroscopy might
improve the prediction of pathologic outcomes for AS.
With the technical advantages of MRI, the recent studies
with MP-MRI had received new consideration in low-risk
prostate cancer. Delongchamps et al. (12) concluded that
MP-MRI could help predict tumor size and bilateral tumor
in unilateral low-risk prostate cancer patients. Furthermore,
Turkbey et al. (13) reported that MP-MRI could estimate
index tumor volume and had better accuracy in prediction of
prostate tumor volume larger than 0.5 cm3 than other clinical
variables. Rouse et al. (23) also reported that MP-MRI could
rule in and rule out clinically signiﬁcant prostate cancer in
men at risk prior to biopsy. Based on these recent ﬁndings,
we supposed that low-risk prostate cancer patients who did
not meet AS inclusion criteria would have different patho-
logic outcomes using tumor visibility on MP-MRI.
In the present study, no visible tumor (cT1c) on MP-MRI
was an independent predictor for organ-conﬁned Gleason
score 6 disease among the non-AS candidates. Our result
supports that MP-MRI could aid the identiﬁcation of suitable
candidates for AS and reduce the misclassiﬁcation using
typical AS inclusion criteria. However, one difference with
other studies is that our concept of misclassiﬁcation is to
identify the low-risk prostate cancer patients who could be
enrolled AS program among non-AS candidate who did not
meet AS criteria. Some readers could raise a question why
the present study focused on the effectiveness of MP-MRI to
identify misclassiﬁed AS candidate among non-AS candi-
date. In fact, almost published literatures had attentions to in-
crease predictive accuracy for organ-conﬁned Gleason 6
disease and/or insigniﬁcant prostate cancer among the AS
candidate. In these literatures, how to identify the unfavor-
able disease among the AS candidates for the predictive
diagnostic accuracy is the main concern (20–23). However,
we investigated it the other way round. Considering there
were clearly considerable proportion of favorable disease
patients among the non-AS candidates whether the AS inclu-
sion criteria are stringent or lenient (8,9), it is also important
to reclassify AS candidate among non-AS candidates.
Another possible question is the pathologic result of AS
candidate who had visible tumor. The proportion of organ-
conﬁned Gleason 6 disease and unfavorable disease fea-
tures in the AS candidates were not signiﬁcantly different
according to tumor visibility. A notable point to explain this
ﬁnding is that the pathologic tumor volume was statistically
different between AS candidate with visible tumor in group
A and non-AS candidate with visible tumor (0.98+ 1.05
versus 1.66+ 1.33 cc, P, 0.001). This difference was also
observed on MRI ﬁndings. The AS candidates had a smaller
tumor diameter on MP-MRI than non-AS candidates
(14.2+ 6.8 versus 16.6+ 7.9 mm, P ¼ 0.004). Considering
that AS programs were developed to identify favorable
disease features with low Gleason score and low tumor
volume, it is hardly surprising that group A patients would
had more favorable disease features than group C patients
even though both groups had visible tumor on MRI.
Recently, Margel et al. (14) reported that MP-MRI could
help to predict disease reclassiﬁcation among prostate cancer
patients who elected to undergo AS. They performed
MP-MRI and conﬁrmatory prostate biopsy to identify
disease progression. In this prospective study, they found
that the patients who had no visible tumor on MP-MRI were
more likely to maintain AS regardless of the conﬁrmatory
biopsy; however, those who had visible tumor were to be re-
classiﬁed from AS program after the conﬁrmatory biopsy.
We believe that their conclusion has similar implications to
Jpn J Clin Oncol 2013;43(5) 557
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our ﬁndings. As the tumor visibility on MP-MRI was an im-
portant indicator for the reclassiﬁcation among the low-risk
prostate cancer patients who elected to undergo AS, it was
also an important indicator for the prediction of organ-
conﬁned Gleason 6 disease among the non-AS candidates.
Our ﬁnding could help urologists agonized the treatment mo-
dality between RP and AS for the low-risk prostate cancer
patients who did not meet the AS criteria. Especially, for the
patients who want AS even though they did not meet AS cri-
teria, tumor visibility on MP-MRI would be helpful with
close surveillance in the clinical practice.
Our study had several limitations. (1) Our study was retro-
spective design and (2) we simply analyzed MP-MRI with the
simple tumor visibility. If we stratiﬁed visible tumors into
more detailed size using maximal tumor diameters, we could
gain more yields of MP-MRI from the study cohort about AS
candidate selection. Actually, we started the analysis using
maximal tumor diameters on MP-MRI and we could be able
to report more meaningful ﬁndings on the role of MP-MRI in
planning treatment for low-risk prostate cancer patients.
However, to measure tumor diameters on MRI is difﬁcult
without accurate interpretation of well-experienced uroradiolo-
gist. So, we reported the efﬁcacy of MP-MRI according to
simple tumor visibility and we thought that this was meaning-
ful. (3) The question could be raised whether the reclassiﬁca-
tion of AS candidates using MP-MRI among non-AS
candidate by current AS protocol is needed. Frankly, the def-
inite management would be needed for the non-AS candidate
who excluded from AS protocols. However, as we mentioned
above, we focused on the possibility of favorable disease
among non-AS candidates in the aspect of increase of beneﬁ-
ciaries of AS. Within this concept, we emphasized that the
non-AS candidate without visible tumor on MP-MRI would
have one more options; AS.
In conclusion, our analysis suggests that low-risk prostate
cancer patient who may not meet AS criteria but who have
no visible tumor on MP-MRI could be selected as AS candi-
date with close surveillance. There were no signiﬁcant differ-
ences in outcome between AS candidates and non-AS
candidate without visible tumors. Therefore, we propose that
the absence of visible tumor on MP-MRI may be reasonably
used in a urologist’s clinical decision when considering a
patient for AS.
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